MDRNA, Valeant Pharmaceuticals International deal

MDRNA acquired patents covering bridged nucleic acids (BNA) from Valeant. MDRNA said the IP is complementary to its unlocked nucleobase analog (UNA) technology, which it is using to develop UsiRNAs fo...